StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $1.41 | $1.38 | -2.11% | 0.1M |
| 05-15 | $1.35 | $1.34 | -0.74% | 0.1M |
| 05-18 | $1.31 | $1.32 | +0.76% | 0.1M |
| 05-19 | $1.31 | $1.34 | +1.93% | 0.0M |
| 05-20 | $1.31 | $1.29 | -1.53% | 0.0M |
No sell-side coverage available for AIDX yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
Fundamentals not available for AIDX yet.
We pull from FMP, Finnhub, and Polygon — common gaps are very recent IPOs that haven't filed their first 10-Q, pink-sheet OTC tickers, and foreign filers without US-listed depth. The Financials tab reads SEC EDGAR directly and may still have data here.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q1 2025 2025-03-31 | Annual 2024 2024-12-31 |
|---|---|---|---|---|
Revenue | $353.38K | $2.05M | $553.82K | $1.75M |
Operating Income | $-1.44M | $-3.33M | $-772.18K | $-5.68M |
Net Income | $-2.17M | $-3.74M | $-764.58K | $-5.55M |
EPS (Diluted) | $-0.28 | $-0.76 | $-0.16 | $-1.16 |
Total Assets | $5.80M | $4.14M | Not available | $3.58M |
Total Liabilities | $3.05M | $4.16M | Not available | $2.08M |
Cash & Equivalents | $4.22M | $1.03M | $1.56M | $1.78M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 10.44M | 5.44M | 4.82M | 4.82M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.